Drugs / KDS-1001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04808115 | Dec 2024 → Dec 2027 | chronic myeloid leukemia | Duke University | Withdrawn | No outcome recorded |
| Phase 1 | NCT04220684 | Jun 2020 → Oct 2024 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Sumithira Vasu | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KDS-1001 | “Six doses of third-party-donor mbIL-21 expanded (KDS-1001) cells given thrice weekly for two weeks.” NCT04220684 ↗ |
| Modality | Cell therapy | “addition of natural killer cell therapy (KDS-1001)” NCT04808115 ↗ |
| Route | Intravenous | “KDS-1001 is infused on Day 1 of each 14 day cycle.” NCT04808115 ↗ |